These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 27649539)
21. Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease. Zhai Y; He H; Ma X; Xie J; Meng T; Dong Y; Lu J Eur J Clin Pharmacol; 2017 Jul; 73(7):843-854. PubMed ID: 28378058 [TBL] [Abstract][Full Text] [Related]
22. Outcomes of patients receiving clopidogrel prior to cardiac surgery. Vorobcsuk A; Aradi D; Farkasfalvi K; Horváth IG; Komócsi A Int J Cardiol; 2012 Apr; 156(1):34-40. PubMed ID: 21112646 [TBL] [Abstract][Full Text] [Related]
23. Association of measured platelet reactivity with changes in P2Y Bagai A; Peterson ED; McCoy LA; Effron MB; Zettler ME; Stone GW; Henry TD; Cohen DJ; Schulte PJ; Anstrom KJ; Wang TY Am Heart J; 2017 May; 187():19-28. PubMed ID: 28454802 [TBL] [Abstract][Full Text] [Related]
24. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel. Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610 [TBL] [Abstract][Full Text] [Related]
25. Outcome comparison of 600 mg versus 300 mg loading dose of clopidogrel for patients with ST-elevation myocardial infarction: a meta-analysis. Vyas A; El Accaoui R; Blevins A; Karrowni W Postgrad Med; 2014 Sep; 126(5):176-86. PubMed ID: 25295662 [TBL] [Abstract][Full Text] [Related]
26. Associations between CYP3A4, CYP3A5 and SCN1A polymorphisms and carbamazepine metabolism in epilepsy: A meta-analysis. Zhao GX; Zhang Z; Cai WK; Shen ML; Wang P; He GH Epilepsy Res; 2021 Jul; 173():106615. PubMed ID: 33756436 [TBL] [Abstract][Full Text] [Related]
27. Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms. Kar R; Meena A; Yadav BK; Yadav R; Kar SS; Saxena R Platelets; 2013; 24(4):297-302. PubMed ID: 22721490 [TBL] [Abstract][Full Text] [Related]
28. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist. Azmoon S; Angiolillo DJ Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463 [TBL] [Abstract][Full Text] [Related]
30. P2Y12 Polymorphisms and the Risk of Adverse Clinical Events in Patients Treated with Clopidogrel: A Meta-Analysis. Zhao K; Yang M; Lu Y; Sun S; Li W; Li X; Zhao Z Drug Res (Stuttg); 2019 Jan; 69(1):23-31. PubMed ID: 29791922 [TBL] [Abstract][Full Text] [Related]
31. Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods. Smock KJ; Saunders PJ; Rodgers GM; Johari V Am J Hematol; 2011 Dec; 86(12):1032-4. PubMed ID: 21812020 [TBL] [Abstract][Full Text] [Related]
32. Associations of P2Y12R gene polymorphisms with susceptibility to coronary heart disease and clinical efficacy of antiplatelet treatment with clopidogrel. Yang HH; Chen Y; Gao CY Cardiovasc Ther; 2016 Dec; 34(6):460-467. PubMed ID: 27566695 [TBL] [Abstract][Full Text] [Related]
33. High-dose atorvastatin on the pharmacodynamic effects of double-dose clopidogrel in patients undergoing percutaneous coronary interventions: The ACHIDO (Atorvastatin and Clopidogrel HIgh DOse in stable patients with residual high platelet activity) study. Leoncini M; Toso A; Maioli M; Angiolillo DJ; Giusti B; Marcucci R; Abbate R; Bellandi F JACC Cardiovasc Interv; 2013 Feb; 6(2):169-79. PubMed ID: 23428009 [TBL] [Abstract][Full Text] [Related]
34. The impact of genetic polymorphisms of drug metabolizing enzymes on the pharmacodynamics of clopidogrel under steady state conditions. Nakkam N; Tiamkao S; Kanjanawart S; Tiamkao S; Vannaprasaht S; Tassaneeyakul W; Tassaneeyakul W Drug Metab Pharmacokinet; 2015 Aug; 30(4):295-304. PubMed ID: 26099919 [TBL] [Abstract][Full Text] [Related]
35. CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population. Guo YM; Zhao ZC; Zhang L; Li HZ; Li Z; Sun HL Genet Mol Res; 2016 May; 15(2):. PubMed ID: 27323099 [TBL] [Abstract][Full Text] [Related]
36. Diversity of platelet function and genetic polymorphism in clopidogrel-treated Chinese patients. Sun B; Li J; Dong M; Yang L; Wu C; Zhu L; Cong YL Genet Mol Res; 2015 Feb; 14(1):1434-42. PubMed ID: 25730082 [TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Velders MA; Abtan J; Angiolillo DJ; Ardissino D; Harrington RA; Hellkamp A; Himmelmann A; Husted S; Katus HA; Meier B; Schulte PJ; Storey RF; Wallentin L; Gabriel Steg P; James SK; Heart; 2016 Apr; 102(8):617-25. PubMed ID: 26848185 [TBL] [Abstract][Full Text] [Related]
38. ADP-receptor inhibitors in the perioperative period: the good, the bad, and the ugly. Oprea AD; Popescu WM J Cardiothorac Vasc Anesth; 2013 Aug; 27(4):779-95. PubMed ID: 23648080 [No Abstract] [Full Text] [Related]
39. Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment. Uchiyama S Cardiovasc Ther; 2011 Dec; 29(6):e100-11. PubMed ID: 21883990 [TBL] [Abstract][Full Text] [Related]
40. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders. Bernlochner I; Byrne RA; Kastrati A; Sibbing D Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]